A double dose of bad news sent the drug company’s share price into freefall.
There was certainly a sense of deja vu for Elan in recent days, as the share price collapsed on the back of two major announcements from the company. It is three years since the stock last had a dramatic tumble and it will no doubt further enforce the view among many investors that Elan carries too much risk.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team